García Arumí, JoséGómez Ulla, FranciscoAmparo, NaveaCervera, EnriqueFonollosa, AlexArias Barquet, LluísAraiz, JavierDonate, JuanSuárez de Figueroa, MartaManzanas, LucíaCrespi, JaumeGallego Pinazo, Roberto2021-05-172021-05-172018-10-142090-004Xhttps://hdl.handle.net/2445/177345Objectives: to evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). Design setting and patients: phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016. Intervention: intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing. Main outcomes: mean change in BCVA after 12 months. Results: 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P=0.0001. Twelve (50.0%) patients gained ≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4 (48.4) µm); P < 0.0001. At Month 12, 8.3% patients had MO. The mean (SD) number of injections: 8.3 (3.0). No treatment-related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported. Conclusions: an aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability.application/pdfengcc-by (c) García Arumí, José et al., 2018https://creativecommons.org/licenses/by/4.0/Malalties de la retinaEdemaEstudi de casosRetinal diseasesEdemaCase studiesinfo:eu-repo/semantics/article6957292021-05-17info:eu-repo/semantics/openAccess30405907